Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2021 Aug 10;20(10):1904–1915. doi: 10.1158/1535-7163.MCT-20-0638

Figure 5.

Figure 5.

Itraconazole inhibits OE33-derived tumor xenograft growth. A, NOD-SCID mice were injected s.c. with 5 × 106 OE33 cells. When tumors formed, mice were randomly divided into 2 groups (control and itraconazole, n = 8). The mice were treated with placebo or itraconazole (80 mg/kg) by oral gavage twice daily for two consecutive weeks. B, Concentrations of itraconazole and its primary metabolite hydroxyitraconazole in esophagi and tumor xenografts from mice treated with placebo or itraconazole. C, Western blot analysis of p-AKT, AKT, p-S6, S6, HER2, p-AMPK, and AMPK expression in OE33-derived xenografts treated with PBS or itraconazole for two weeks. GAPDH is used as a loading control. D, Representative immunohistochemical staining of p-S6 from xenograft sections treated with placebo or itraconazole. Scale bar: 100 μm.